TITLE

Limitations of HbA[sub1c] in diabetes control

PUB. DATE
March 2003
SOURCE
Pulse;3/24/2003, Vol. 63 Issue 12, p88
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Discusses the limitations of the HbA[sub 1c] in aiding the treatment of type 2 diabetes. Method of monitoring the effectiveness of therapy in diabetes; Clinical advantages of measuring fructosamine level.
ACCESSION #
9456058

 

Related Articles

  • Updated guidelines for type 2 diabetes.  // Critical Care Alert;Dec2008 Pharmacology Watch, p2 

    The article reports on the American Diabetes Association and the European Association for the Study of Diabetes' updated treatment guidelines and algorithms for the treatment of type 2 diabetes.

  • Untitled. Anderson, Sarah L. // Pharmacy Today;Sep2011 Supplement, p2 

    An introduction is presented in which the editor discusses the significance of an oral dipeptidyl peptidase-4 (DDP-4) inhibitor called Tradjenta to treat type 2 diabetes mellitus (T2DM) and the epidemiological data of diabetes in the U.S.

  • Miglitol: A Review of its Therapeutic Potential in Type 2 Diabetes Mellitus. Scott, L.J.; Spencer, C.M. // Drugs;Mar2000, Vol. 59 Issue 3, p521 

    Miglitol, the first pseudomonosaccharide α-glucosidase inhibitor, smooths postprandial peak plasma glucose levels and thus improves glycaemic control, which is reflected in a reduced glycosylated haemoglobin (HbA) level. This oral antihyperglycaemic agent is indicated for the treatment of...

  • Repaglinide: A Review of its Therapeutic Use in Type 2 Diabetes Mellitus. Culy, C.R.; Jarvis, B. // Drugs;Aug2001, Vol. 61 Issue 11, p1625 

    Repaglinide, a carbamoylmethyl benzoic acid derivative, is the first of a new class of oral antidiabetic agents designed to normalise postprandial glucose excursions in patients with type 2 diabetes mellitus. Like the sulphonylureas, repaglinide reduces blood glucose by stimulating insulin...

  • Alpha-Tocopherol Induces Leptin Expression in Healthy Individuals and In Vitro. Isermann, Berend; Bierhaus, Angelika; Tritschler, Hans; Ziegler, Reinhard; Nawroth, Peter Paul; Shimizu, Hiroyuki; Tsuchiya, Takahumi; Mori, Masatomo // Diabetes Care;Jul99, Vol. 22 Issue 7, p1227 

    Presents comments and responses on the effect of troglitazone on plasma leptin concentration in poorly controlled type 2 diabetic patients. Information on a study on the effect of oxidative stress on leptin expression; Recommendation on further studies evaluating plasma leptin concentrations in...

  • New diabetes treatments may be on horizon.  // Diabetes in the News;Nov/Dec94, Vol. 13 Issue 6, p3 

    Reports on studies regarding new therapies for type II diabetes. Food and Drug Administration's (FDA) pending approval of an oral agent called metformin; Studies on thiazoles and vanadates; Mechanism of action of tolrestat; Use of combination drug approach in diabetes-related impotence; Use of...

  • Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes.  // Formulary;Feb2010, Vol. 45 Issue 2, p34 

    An abstract of the article "Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes," by Ashley Krause and Jennifer Kirwin is presented.

  • Managing Obesity as First-Line Therapy for Diabetes Mellitus. Kelley, David E. // Nutrition in Clinical Care;Jan/Feb98 Supplement 1, Vol. 1 Issue 1, p38 

    Focuses on the management of obesity for the treatment of type 2 diabetes mellitus in the United States. Improvement of weight loss in obese patients; Impact of weight loss on the clinical efficacy of concominant pharmacologic therapy; Reduction of skeletal muscles insulin resistance.

  • Newer, controlled-release glipizide is superior to its conventional form.  // Modern Medicine;Mar95, Vol. 63 Issue 3, p53 

    Presents an abstract of the article `Comparative Efficacy of a Once-daily Controlled-Release Formulation of Glipizide and Immediate-Release Glipizide in Patients With NIDDM,' by M. Berelowitz, C. Fischette et al dated December 1994.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics